NCT04808817View on ClinicalTrials.gov

Relationship Between Immunity and Metabolism in Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer. ( RIMEC )

NAActive, not recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 10, 2021

Primary Completion Date

April 9, 2024

Study Completion Date

October 9, 2024

Conditions
Metabolism DisorderCancerImmune Checkpoint Inhibitors
Interventions
DIAGNOSTIC_TEST

calorimetry, impedance measurement at baseline and after 3 months of treatment

biobanking (30ml) for cytokines and complement dosages at baseline and after 3 months of treatment calorimetry and impedance measure will be collected at baseline and after 3 months of ICI treatment

Trial Locations (2)

75014

Hôpital Cochin, Paris

75015

AP-HP - Hôpital Européen Georges-Pompidou Paris, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER